Neumora Therapeutics, Inc. Intellectual Property Contracts & Agreements
9 Contracts & Agreements
- License Agreements (9 contracts)
- Second Amendment to License Agreement, dated May 17, 2024, by and between the Registrant and Vanderbilt University (Filed With SEC on August 6, 2024)
- First Amendment to Exclusive License Agreement for GCase, dated June 14, 2022, by and between the Registrant and Amgen, Inc (Filed With SEC on September 11, 2023)
- First Amendment to License Agreement, dated July 17, 2023, by and between the Registrant and Vanderbilt University (Filed With SEC on August 25, 2023)
- License Agreement, dated February 10, 2022, by and between the Registrant and Vanderbilt University (Filed With SEC on August 25, 2023)
- Second Amendment to License Agreement, dated April 9, 2019, by and between BlackThorn Therapeutics, Inc. and Scripps Research Institute (Filed With SEC on August 25, 2023)
- First Amendment to License Agreement, dated November 13, 2017, by and between BlackThorn Therapeutics, Inc. and Scripps Research Institute (Filed With SEC on August 25, 2023)
- License Agreement, dated November 23, 2015, by and between BlackThorn Therapeutics, Inc. and Scripps Research Institute (Filed With SEC on August 25, 2023)
- Exclusive License Agreement for GCase, dated September 10, 2021, by and between the Registrant and Amgen Inc (Filed With SEC on August 25, 2023)
- Exclusive License Agreement for CK1d, dated September 10, 2021, by and between the Registrant and Amgen Inc (Filed With SEC on August 25, 2023)
